PF-06671008 Dose Escalation Study in Advanced Solid Tumors
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression. The study will then expand to look at the selected dose in patients with P-cadherin expressing TNBC, CRC or NSCLC.
Checked against the public recordLast updated May 6, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Pfizer
- Interventions being studied
- Drug: PF-06671008; Drug: PF-06671008
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Key Inclusion Criteria * Diagnosis of tumor type with the potential to have P-cadherin expression that is resistant to standard therapy or for which no standard therapy is available * Performance status of 0 or 1 * Adequate bone marrow, kidney and liver function Key Exclusion Criteria * Known CNS disease including, but not limited to, metastases * Current or history of seizure disorder * History of or active autoimmune disorders * Active bacterial, fungal or viral infection * Major surgery, anti-cancer therapy, or radiation therapy within 4 weeks of study treatment * Requirement for systemic immune suppressive medication * Grade 2 or greater peripheral neuropathy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Memorial Sloan Kettering Cancer Center - WestchesterHarrison, New York
- Memorial Sloan Kettering Cancer Center- Clinical Trials OfficeNew York, New York
- Memorial Sloan Kettering Cancer Center Rockefeller Outpatient PavillionNew York, New York
- Memorial Sloan Kettering Cancer CenterNew York, New York
- University Hospitals Cleveland Medical CenterCleveland, Ohio
- The University of Texas - M.D. Anderson Cancer CenterHouston, Texas
- The University of Texas MD Anderson Cancer CenterHouston, Texas
- Huntsman Cancer HospitalSalt Lake City, Utah
- Huntsman Cancer InstituteSalt Lake City, Utah
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 6, 2020. Always confirm current availability with the study team.